Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)

Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell. In early-stage disease, lesions are limited to the skin, but in later-stage disease, the tumor cells can escape into the blood, the lymph nodes, and at times the visceral organs. To clarify the genomic b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Jg. 130; H. 12; S. 1430
Hauptverfasser: Park, Joonhee, Yang, Jingyi, Wenzel, Alexander T, Ramachandran, Akshaya, Lee, Wung J, Daniels, Jay C, Kim, Juhyun, Martinez-Escala, Estela, Amankulor, Nduka, Pro, Barbara, Guitart, Joan, Mendillo, Marc L, Savas, Jeffrey N, Boggon, Titus J, Choi, Jaehyuk
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 21.09.2017
Schlagworte:
Amino Acid Sequence
Amino Acid Substitution - genetics
Base Sequence
Genome, Human
Genomics
HEK293 Cells
Humans
Jurkat Cells
Lymphoma, T-Cell, Cutaneous - genetics
Microfilament Proteins - chemistry
Microfilament Proteins - genetics
Mutation - genetics
NF-kappa B - metabolism
Oncogenes
Receptors, Antigen, T-Cell - metabolism
rhoA GTP-Binding Protein - genetics
Sequence Analysis, DNA
Signal Transduction - genetics
ISSN:1528-0020, 1528-0020
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell. In early-stage disease, lesions are limited to the skin, but in later-stage disease, the tumor cells can escape into the blood, the lymph nodes, and at times the visceral organs. To clarify the genomic basis of CTCL, we performed genomic analysis of 220 CTCLs. Our analyses identify 55 putative driver genes, including 17 genes not previously implicated in CTCL. These novel mutations are predicted to affect chromatin ( , , , ), immune surveillance ( , ), MAPK signaling ( , ), NF-κB signaling ( , ), PI-3-kinase signaling ( , ), RHOA/cytoskeleton remodeling ( ), RNA splicing ( ), T-cell receptor signaling ( , ), and T-cell differentiation ( ). Our analyses identify recurrent mutations in 4 genes not previously identified in cancer. These include CK1α (encoded by ) (p.S27F; p.S27C), PTPRN2 (p.G526E), RARA (p.G303S), and RLTPR (p.Q575E). Last, we functionally validate and as putative oncogenes. encodes a recently described scaffolding protein in the T-cell receptor signaling pathway. We show that RLTPR (p.Q575E) increases binding of RLTPR to downstream components of the NF-κB signaling pathway, selectively upregulates the NF-κB pathway in activated T cells, and ultimately augments T-cell-receptor-dependent production of interleukin 2 by 34-fold. Collectively, our analysis provides novel insights into CTCL pathogenesis and elucidates the landscape of potentially targetable gene mutations.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1528-0020
1528-0020
DOI:10.1182/blood-2017-02-768234